首页> 美国卫生研究院文献>other >Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials

【2h】

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials

机译：在第三阶段辅助化疗试验的第三阶段结肠癌复发后BRAF和KRAS中DNA错配修复和突变与存活率的关系

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

ImportanceThe association of biomarkers with patient survival after recurrence (SAR) is poorly understood, yet may guide management and treatment.

机译：重要性生物标志物与患者复发后存活率（SAR）的关联了解甚少，但仍可指导治疗和治疗。

著录项

期刊名称 other
作者
Frank A. Sinicrope; Qian Shi; Carmen J. Allegra; Thomas C. Smyrk; Stephen N. Thibodeau; Richard M. Goldberg; Jeffrey P. Meyers; Kay L. Pogue-Geile; Greg Yothers; Daniel J. Sargent; Steven R. Alberts;
展开▼
作者单位

展开▼
年(卷),期 -1(3),4
年度 -1
页码 472–480
总页数 17
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). [J] . Harry H Yoon, David Tougeron, Qian Shi, Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第11期

机译：来自BRAF野生型III期结肠癌的无病生存的KRAS密码子12和13突变来自辅助化疗试验（N0147联盟）。
2. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study [J] . Andre Thierry, de Gramont Armand, Vernerey Dewi, Journal of Clinical Oncology . 2015,第35期

机译：II至III期结肠癌的辅助氟尿嘧啶，叶绿素和奥沙利铂：根据MOSAIC研究的BRAF突变和不匹配修复状态，更新的10年生存率和结果
3. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials [J] . SinicropeF.A., FosterN.R., YoonH.H., Journal of Clinical Oncology . 2012,第4期

机译：参加NCCTG和NSABP辅助化疗试验的II或III期结肠癌患者的肥胖与DNA错配修复状态和临床结局的关系
4. Adjuvant Chemotherapy Should Not Routinely Be Recommended to Patients with Stage II Colon Cancers that Manifest Microsatellite Instability [C] . Sigurdis Haraldsdottir, Richard M. Goldberg Gastrointestinal Cancers Symposium . 2014

机译：不应常规向患有阶段结肠癌的患者常规的辅助化学疗法，表明微卫星不稳定性
5. The Association of Hospital and Patient Characteristics with Treatment Initiation among Veterans with Stage I, II, or III Lung, Colon or Rectal Cancer [D] . Clary, Alecia S. 2019

机译：具有阶段I，II或III肺，结肠或直肠癌的退伍军人治疗发起的医院和患者特征
6. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance) [O] . Harry H. Yoon, David Tougeron, Qian Shi, -1

机译：辅助化疗试验（N0147联盟）中与BRAF野生型III期结肠癌的无病生存相关的KRAS密码子12和13突变
7. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status [O] . Thierry André, null null, Timothy Iveson, 2013

机译：IDEA（国际辅助化疗持续时间评估）合作：III期试验的前瞻性联合分析，研究针对III期结肠癌患者的FOLFOX（FOLFOX4或改良的FOLFOX6）或XELOX（3个月至6个月）方案的辅助治疗的持续时间的III期试验：试验设计与现状

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅